Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 4Recruiting 2Not yet recruiting 2Active not recruiting 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Classical hematology 2

Conditions

Myeloproliferative Disorders 2Anemia 2Primary Myelofibrosis 1Myelodysplastic Syndromes 1

Interventions

pembrolizumab 436Carboplatin 321Nivolumab 287Cyclophosphamide 280Specimen Handling 257Cisplatin 251Paclitaxel 248Magnetic Resonance Spectroscopy 248Radiotherapy 217Gemcitabine 180Dexamethasone 180Biopsy 177durvalumab 166atezolizumab 148Rituximab 138Lenalidomide 134Doxorubicin 134Docetaxel 130Bevacizumab 129Ipilimumab 125Radiation 118Capecitabine 117Pemetrexed 112Oxaliplatin 112Etoposide 111Radiosurgery 108Fluorouracil 108venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × luspatercept × Clear all
NCT05732961 2026-05-05

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
6 enrolled
Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT04717414 2025-07-10

INDEPENDENCE

Celgene

Phase 3 Active not recruiting
313 enrolled
Classical hematologyMyeloid

Anemia, Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡